Title of Invention

MATRIX METALLOPROTEINASE INHIBITOR COMPOUNDS

Abstract Compounds of Formula (la) : Wherein T is absent, represents optional bonds, G1 and G2 each independently represents CH or N, A represents bond, C1-6alkyl or CH=CH-C1-4alkyl, B represents bond, O, S, SO, SO2, CO, CR7R8, CO2R14, CONR14R15, N(COR14)(COR15), N(SO2R14)(COR15), NR14R15, D represents bond, or C1-6 alkyl, E represents aryl substituted by one or more of C1-6 alkyl, C2-6 alkenyl, halogen, C1-6 alkoxy, cyano, hydroxy, nitro, amino, - N(CH3)2, -NHCOC1-6 alkyl, -OCF3, -CF3, -COOC1-6 alkyl, -OCHCF2, -SCF3, -CONR5R6 - SO2N(CH3)2, -SO2CH3 or -SCH3 groups, or by fused cycloalkyl or heterocyclic rings which may themselves be substituted, for example by carbonyl groups;or unsubstituted heteroaryl; or heteroaryl substituted by one or more of C1-6 alkyl, C2-6 alkenyl, halogen, C1-6 alkoxy, cyano, hydroxy, nitro, amino, -N(CH3)2, -NHCOC1-6 alkyl, -OCF3, -CF3, -COOC1-6 alkyl, -OCHCF2, -SCF3, -CONR5R6 -SO2N(CH3)2, -SO2CH3 or -SCH3 groups, or by fused cycloalkyl or heterocyclic rings which may themselves be substituted, for example by carbonyl groups; wherein heteroaryl means mono- or bicyclic heterocyclic aromatic rings containing 1-3 hetero atoms selected from nitrogen, oxygen and sulphur, R5 and R6 each independently represent H, C1-6 alkyl or C1-4 alkylaryl, R7 and R8 each independently represent H, halo, C1-6 alkyl or C1-4 alkylaryl, R14 and R15 each independently represents H, C1-6 alkyl or C1-4 alkylaryl or C1-4 alkylheteroaryl or together with the functionality to which they are attached R14 and R15 from a heterocyclic or fused heterocyclic group which may contain one or more further atoms selected from C, O, N and S, R16 represents H, C1-6 alkyl or C1-4 alkylaryl, R17 represents H or C1-6 alkyl, R18 and R19 each independently represents halo, cyano, nitro, OR16, SR16, COR16, NR17COR16, CONR16R17, optionally substituted phenoxy or C1-6alkyl optionally substituted by OR16, m and n each independently represents 0 or an integer 1,2 or 3and pharmaceutically acceptable esters, amides and carbamates, salts and solvates thereof.
Full Text Matrix Metalloproteinase Inhibitor compounds
This invention relates to novel chemical compounds, processes for their preparation,
pharmaceutical formulations containing them and their use in therapy.
The compounds of the invention are inhibitors of matrix metalloproteinase enzymes
(MMPs).
Matrix metalloproteinase enzymes play a major role in extracellular matrix component
degradation and remodelling. Examples of MMPs include collagenase 1, 2 and 3,
gelatinase A and B, stromelysin 1,2 and 3, matrilysin, macrophage metalloelastase,
enamelysin and membrane type 1,2,3 and 4 MMP. The enzymes are secreted by
connective tissue cells and inflammatory cells. Enzyme activation can not only initiate
tissue damage but induce increased inflammatory cell infiltration into the tissue, leading
to more enzyme production and subsequent tissue damage. For example, elastin
fragments produced by MMP degradation are believed to stimulate inflammation by
attracting macrophages to the site of MMP activity. Inhibition of MMPs provides a
means for treating disease states wherein inappropriate metalloprotease activity results
in degradation of connective tissue and inflammation.
In one aspect, the present invention provides compounds of formula (I):

Wherein:
A represents bond, C^alkyl or CH=CH-C1^alkyl;
B represents bond, O, S, SO, S02, CO, CR7P.8, C02R14, CONR,4R15, N(COR14)(COR15),
N(S02R14)(COR15) or NR14R15;
D represents bond, or Ci^alkyl;
E represents substituted aryl or substituted or unsubstituted heteroaryl;
Q represents an optionally substituted 5- or 6-membered aryl or heteroaryl ring;
X represents O, S, SO, S02, CO, CNR5, CNOR5, CNNR5R6, NR11 or CR7R8;
Y represents CR5OR11, CR5SR11, NOR5, CR5NR6R11, SO, S02, CO, CNR5, CNOR5 or CS;
R1 and R1 each independently represents H, C^alkyl or C-i^alkylaryl;
R2 represents C02R12, CH2OR12 or CONR12R13, CONR12OR13, NR12COR13, SR12,
PO(OH)2, PONHR12 or SONHR12;

R3 represents H, C1-6alkyl or C1-4alkylaryl;
R4 represents optionally substituted aryl or heteroaryl;
Z represents a bond, CH2, O, S, SO, SO2, NR5, OCR5R6, CR9R10O or Z, R4 and Q
together form an optionally substituted fused tricyclic group;
R5 and R6 each independently represent H, C1-6 alkyl or C1-4 alkylaryl;
R7 and R8 each independently represent H, halo, C1-6 alkyl or C1-4 alkylaryl;
R9 and R10 each independently represents H, d-6 alkyl optionally substituted by halo,
cyano, OR11 or NR6R11 , C1-4 alkylaryl optionally substituted by halo, cyano, OR11 or
NR6R11, OR11 or, together with the N to which they are attached, R9 and R10 form a
heterocyclic group optionally containing one or more further heteroatoms selected from O,
N and S;
R11 represents H, C1-6 alkyl, C1-4 alkylaryl or COR5;
R12and R13 each independently represent H, C1-3 alkyl, C1-3 alkylaryl or C1-3 alkylheteroaryl
or, together with the functionality to which they are attached, R12 and R13 form a
heterocyclic group optionally containing one or more further atoms selected from C, O, N
and S;
R14 and R15 each independently represent H, C1-6 alkyl, C1-4 alkylaryl or C1-4
alkylheteroaryl or together with the functionality to which they are attached R14 and R15
form a heterocyclic or fused heterocyclic group which may contain one or more further
atoms selected from C, O, N and S; and physiologically functional derivatives thereof.
References to 'aryl' include references to monocyclic carbocyclic aromatic rings (e.g.
phenyl) and bicyclic carbocyclic aromatic rings (e.g. naphthyl) and references to
'heteroaryl' include references to mono- and bicyclic heterocyclic aromatic rings
containing 1-3 hetero atoms selected from nitrogen, oxygen and sulphur. In a bicyclic
heterocyclic aromatic group there may be one or more hetero-atoms in each of the rings,
or only in one ring. Examples of monocyclic heterocyclic aromatic rings include pyridinyl,
pyrimidinyl, thiophenyl, furanyl, pyrrolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazoly!,
thiadiazolyl, uracil or imidazolyl, and examples of bicyclic heterocyclic aromatic rings
include benzofuranyl, benzimidazolyl, quinolinyl or indolyl. Carbocyclic and heterocyclic
aromatic rings may be optionally substituted, e.g. by one or more C1-6 alkyl, C2-6 alkenyl,
halogen, C1-6 alkoxy, cyano, hydroxy, nitro, amino, -N(CH3)2, -NHCOC1-6 alkyl, -OCF3, -
CF3, -COOC1-6 alkyl, -OCHCF2, -SCF3, -CONR6R7 -SO2N(CH3)2, -SO2CH3 or -SCH3
groups, or by fused cycloalkyl or heterocyclic rings which may themselves be substituted,
for example by carbonyl groups.
References to 'alkyl' include references to both straight chain and branched chain
aliphatic isomers of the corresponding alkyl. It will be appreciated that references to
alkylene and alkoxy shall be interpreted similarly.
Suitably A represents bond or C1-6 alkyl, such as C2 or C3 alkyl.
Suitably B represents bond.

Suitably D represents methylene or bond, preferably bond.
For Example A-B-D may suitably represent -CH2CH2-.
Optional substituents for E include one or more of C1-6 alkyl, C2-6 alkenyl, halogen, C1-6
alkoxy, cyano, hydroxy, nitro, amino, -N(CH3)2, -NHCOC1-6 alkyl, -OCF3, -CF3, -COOC1-6
alkyl, -OCHCF2, -SCF3, -CONR5R6 -S02N(CH3)2, -SO2CH3 or -SCH3 groups, or by fused
cycloalkyl or heterocyclic rings which may themselves be substituted, for example by
carbonyl groups.
In one subgroup of compounds according to the invention, E represents substituted or
unsubstituted 5- or 6- membered heteroaryl such as a nitrogen-containing heteroaromatic
group, for example, uracil.
In a further subgroup of compounds according to the invention, E represents aryl, such as
phenyl, substituted by a fused substituted or unsubstituted heterocyclic ring, such as a
nitrogen-containing heterocyclic ring. Exemplary of this subgroup are compounds
according to the invention wherein E represents phthalimido.
Suitable optional substituents for Q include one or more of C1-6 alkyl, C2-6 alkenyl, halogen,
C1-6 alkoxy, cyano, hydroxy, nitro, amino, -N(CH3)2, -NHCOC1-6 alkyl, -OCF3, -CF3, -
COOC1-6 alkyl, -OCHCF2, -SCF3, -CONR5R5-SO2N(CH3)2, -SO2CH3 or -SCH3 groups.
Most suitably Q represents unsubstituted phenyl.
Suitably, R1 and R1 each represents hydrogen.
Suitably R2 represents CO2R12 such as CO2H.
Suitably R3 represents hydrogen.
Suitably R4 benzofuranyl, phenyl or pyrimidinyl. Suitable optional substituents for R4
include one or more of C1-6 alkyl, C2-6 alkenyl, halogen, C1-6 alkoxy, cyano, hydroxy, nitro,
amino, -N(CH3)2, -NHCOC1-6 alkyl, -OCF3, -CF3, -COOC1-6 alkyl, -OCHCF2, -SCF3, -
CONR5R6, -SO2N(CH3)2, -SO2CH3 or -SCH3 groups. Preferably R4 represents optionally
substituted phenyl or optionally substituted pyrimidinyl.
Suitably X represents CH2.
Suitably Y represents CHOR11, where R11 suitably represents H, C1-6 alkyl or COR5.
Preferably R11 represents H. R5 preferably represents C1-6 alkyl.

Suitably Z represents a bond, or Z, R4 and Q together represent a fused tricyclic group.
Preferably, Z represents a bond.
A subgroup of compounds of formula (I) is presented by formula (la) and formula (lb):

wherein:
T is absent or represents O, S, NR16 or CR16R17;
— represents optional bonds;
G1 and G2 each independently represents CH or N;
A represents bond, C1-6alkyl or CH=CH-C1-4alkyl;
B represents bond, O, S, SO, SO2, CO, CR7R8, CO2R14. CONR14R15, N(COR14)(COR15),
N(SO2R14)(COR15), NR14R15;
D represents bond, or C1-6 alkyl;
E represents substituted aryl or substituted or unsubstituted heteroaryl;
R16 represents H, C1-6alkyl or C1-4alkylaryl;
R17 represents H or C1-6 alkyl;
R18 and R19 each independently represents halo, cyano, nitro, OR16, SR16, COR16,
NR17COR16, CONR16R17, optionally substituted phenoxy or C1-6alkyl optionally substituted
by OR16;
m and n each independently represents 0 or an integer 1,2 or 3; and physiologically
functional derivatives thereof.
In compounds of formulae (la) and (lb), A suitably represents alkyl, such as C1-4alkyl, for
example ethyl. Suitably, B represents bond. Suitably D represents bond. Suitably E
represents substituted or unsubstituted heteroaryl such as nitrogen-containing heteroaryl.

for example uracil , or E represents phenyl substituted by a fused substituted or
unsubstituted heterocyclic ring, such as phthalimido.
Preferably n is 0 and m is 1.
Preferably R18 represents a para-substituent selected from NO2, C1-6 alkyl, C1-6 alkoxy,
halo, SC1-6 alkyl, CN and COC1-6 alkyl.
Preferably, G1 and G2 are both CH or both N.
A further subgroup of compounds according to the invention is represented by
compounds of formula (Ic):

wherein A,B,D,E,R18 and m are as defined for formulae (la) and (lb) above; and
physiologically functional derivatives thereof.
In compounds of formula (Ic), A-B-D suitably represents -CH2-CH2-. Suitably m
represents 0 or 1. When m is 1, R18 suitably represents a para substituent selected from
NO2, C1-6 alkyl, C1-6 alkoxy, halo, SC1-6 alkyl, CN, OCF3, or COC1-6 alkyl.
A further subgroup of compounds according to the intention is represented by compounds
of formula (Id):

wherein R20 represents a substituted or unsubstituted aryl or heteroaryl group selected
from phenyl, benzofuraryl and pyrimidinyl; and


represents a substituted aryl or a substituted or unsubstituted heteroaryl group comprising
at least one nitrogen atom; and physiologically functional derivatives thereof.
In compounds of formula (Id), R20 suitably represents unsubstituted or substituted phenyl,
unsubstituted benzofuraryl or unsubstituted pyrimidinyl. When R20 represents substituted
phenyl, suitably the phenyl ring will be substituted by a single substituent in the para
position. Suitable substituents include C1-6alkyl, C2-6alkenyl, halogen, C1-6alkoxy, cyano,
hydroxy, nitro, amino, -N(CH3)2, -NHCOC1-6alkyl, -OCF3, -CF3, -CO2C1-6alkyl, OCHCF2, -
SCF3, -CONR5R6, -SO2N(CH3)2, -SO2CH3 or -SCH3, such as cyano, COCH3, OCF3 and
SCH3.
By the term "physiologically functional derivative" is meant a chemical derivative of a
compound of formula (I) having the same physiological function as the free compound of
formula (I), for example, by being convertible in the body thereto and includes any
pharmaceutically acceptable esters, amides and carbamates, salts and solvates of
compounds of formula (I) which, upon administration to the recipient, are capable of
providing (directly or indirectly) compounds of formula (I) or active metabolite or residue
thereof.
Suitable salts of the compounds of formula (I) include physiologically acceptable salts and
salts which may not be physiologically acceptable but may be useful in the preparation of
compounds of formula (I) and physiologically acceptable salts thereof. If appropriate, acid
addition salts may be derived from inorganic or organic acids, for example hydrochlorides,
hydrobromides, sulphates, phosphates, acetates, benzoates, citrates, succinates,
lactates, tartrates, fumarates, maleates, 1-hydroxy-2-naphthoates. palmoates,
methanesulphonates, formates or trifluoroacetates.
Examples of solvates include hydrates.
When compounds of formula (I) contain chiral centres, the invention extends to mixtures
of enantiomers (including racemic mixtures) and diastereoisomers as well as to individual
enantiomers. Generally it is preferred to use a compound of formula (I) in the form of a
purified single enantiomer. Enantiomerically pure compounds of formula (I) are available
by way of chirally selective synthesis or by way of chiral separation.
The compounds of formula (I) and salts and solvates thereof may be prepared by the
methodology described hereinafter, constituting a further aspect of this invention.
A first process (A) according to the invention for preparing a compound of formula (I)
wherein Z represents a bond comprises reacting a compound of formula (II):


wherein R1, R1', R2, R3, R3', A, B, D, E, Q, X and Y are as previously defined for formula (I)
and L represents a leaving group, with a reagent suitable to introduce the group R4, such
as a compound R4B(OH)2, suitably in the presence of a catalyst, such as a noble metal
catalyst e.g. palladium, and a suitable base, such as an alkali metal carbonate, e.g.
caesium carbonate. The reaction is conveniently carried out in a suitable solvent, such as
a polar organic solvent, e.g. dimethyl formamide. Suitable leaving groups represented by
L include halides, especially bromide or iodide.
For example, for the synthesis of a (optionally substituted) biphenyl compound according
to the invention (ie Q and R4 are both phenyl), a phenyl boronic acid may be reacted with
[(4-bromophenyl)(methylsulfonyl)amino]acetic acid in the presence of a suitable catalyst:

A second process (B) according to the invention for preparing a compound of formula (I)
wherein Z represents O, S, SO, SO2, or NR5, comprises reacting a compound of formula
(III):

wherein Q, X, Y, R1, R1', R2, R3, A, B, D and E are as previously defined for formula (I),
and T represents OH, SH or NR6H, with a reagent suitable to introduce the group R4, such
as a compound R4-L, wherein L is a suitable leaving group. The reaction is conveniently
carried out in a suitable solvent, such as a solvent containing a heteroatom, e.g. pyridine
in the presence of a suitable catalyst, for example a palladium catalyst (preferred for T =
NR5H) or a copper catalyst (preferred for T = OH or SH). Suitable leaving groups
represented by L include halides, especially bromide or iodide.
For compounds in which Z represents SO or SO2, the compound of formula (I) may
conveniently be prepared by initial preparation of the compound in which Z represents S,

followed by oxidation of the sulphide to the sulfoxide or the sulfone. The oxidation step
may be carried out using methods known in the art such as oxidation with hydrogen
peroxide in the case of the sulfone, or oxidation with Oxone® (potassium
peroxymonosulfate) in the case of the sulfoxide.
A third process (C) according to the invention for preparing a compound of formula (I)
wherein Z represents OCR5R6, comprises reacting a compound of formula (IV):

wherein Q, X, Y, R1, R1', R2, R3, R5, R6, A, B, D and E are as previously defined for
formula (I), with a reagent suitable to introduce the group R4-O such as a compound R4-
OH. The reaction is conveniently carried out in a suitable solvent, such as an alcohol
solvent, e.g. ethanol, under basic conditions, for example in the presence of an aqueous
hydroxide such as sodium hydroxide. Suitable leaving groups represented by L include
halides, especially bromide or iodide.
A fourth process (D) according to the invention for preparing a compound of formula (I)
wherein Z represents CR5R6O, comprises reacting a compound of formula (V):

wherein Q, X, Y, R1, R1', R2, R3, A, B, D and E are as previously defined for formula (I),
with a reagent suitable to introduce the group R4CR5R6 such as a compound R4CR5R6-L,
wherein L is a suitable leaving group. The reaction is conveniently carried out in a
suitable solvent, such as an alcohol solvent, e.g. ethanol, under basic conditions, for
example in the presence of an aqueous hydroxide such as sodium hydroxide. Suitable
leaving groups represented by L include halides, especially bromide or iodide.
A fifth process (E) according to the invention for preparing a compound of formula (I)
wherein Z represents CH2, comprises reacting a compound of formula (VI):


(VI)
wherein Q, X, Y, R1, Rr, R2, R3, A, B, D and E are as previously defined for formula (I),
with a reagent suitable to introduce the group R4CH2, such as a compound R4CH2-L,
wherein L is a suitable leaving group, for example halide, suitably in the presence of a
catalyst, for example a Lewis acid catalyst such as AICI3. A Friedel-Crafts reaction may
accordingly be appropriate.
A sixth process (F) according to the invention for preparing a compound of formula (I)
comprises reacting a compound of formula (VII)

wherein Q, X, Y, R1, R1', R2, R3, R4, A, B and D are as previously defined for formula (I),
with a reagent suitable to introduce the group E such as a compound H-E. The reaction is
conveniently carried out in a suitable solvent, such as an aprotic solvent, e.g.
dimethylformamide, under basic conditions, for example in the presence of a base such
as potassium hydride. Suitable leaving groups represented by L include halides, such as
bromide or iodide, and methylsulphonyloxy groups.
A seventh process (G) according to the invention comprises carrying out a process
selected from processes (A) to (F) followed by interconversion of one or more functional
groups. Interconversion processes include processes such as oxidation, reduction,
substitution, deprotection etc., standard in the art of synthetic chemistry.
Compounds of formula (II), (III), (IV). (V) and (VI) may be prepared by reaction of
compounds of formula (VIII):

wherein Q, X, Y, R1, R1', R2, R3, A, B and D are as previously defined for formula (I) and U
is L in the case of compound (II), T in the case of compound (III), L(R5)(R6)CH2 in the case
of compound (IV), OH in the case of compound (V) and H in the case of compound (VI),
and L2 represents a leaving group more labile than L, with a compound of formula E-H or
a salt of formula E-M+. Suitable leaving groups represented by L2 include halides, such as
bromide or iodide, and methylsulphonyloxy groups. Alternatively, an activated leaving

group L2 of the Mitsunobu type may be generated by reacting a corresponding alcohol
with diisopropylazodicarboxylate and triphenylphosphine; that leaving group may then be
displaced by an anion E-M+ to generate the product.
Compounds of formula (VIII) may in turn be prepared by reaction of compounds of
formula (IX):

wherein Q, X, Y, R1, R1', R2 and R3 are as previously defined for formula (I), U is as
previously defined for formula (VIII) and L3 represents a leaving group, with a compound
of formula H-A-B-D-L2. The reaction is conveniently carried out in a suitable solvent, such
as an aprotic solvent, e.g. dimethylformamide in the presence of a suitable catalyst, for
example a metal hydride.
Compounds of formula (IX) may in turn be prepared by reaction of compounds of formula
(X) with compounds of formula (XI):

wherein Q, X, Y, R1, R1', R2 and R3 are as previously defined for formula (I), U is as
previously defined for formula (VIII), L3 is as previously defined for formula (IX), and L4
represents a leaving group. The reaction is conveniently carried out in a suitable solvent,
such as an aprotic solvent, e.g. tetrahydrofuran in the presence of a suitable catalyst, for
example a metal hydride.
Analogously, compounds of formula (VII) may be prepared by reaction of compounds of
formula (XII):
wherein Q, X, Y, R1, R1', R2, R3 and R4 are as previously defined for formula (VII), and L3
represents a leaving group, with a compound of formula H-A-B-D-L. The reaction is

conveniently carried out in a suitable solvent, such as an aprotic solvent, e.g.
dimethylformamide in the presence of a suitable catalyst, for example a metal hydride.
Compounds of formula (XII) may in turn be prepared by reaction of compounds of formula
(XIII) with compounds of formula (XIV):

wherein Q, X, Y, R1, R1', R2, R3and R4 are as previously defined for formula (I) L3 is as
previously defined for formula (XII), and L4 represents a leaving group. The reaction is
conveniently carried out in a suitable solvent, such as an aprotic solvent, e.g.
tetrahydrofuran in the presence of a suitable catalyst, for example a metal hydride.
Compounds of formula R4B(OH)2t R4-L, R4-OH, R4CR5R6-L, R4CH2-L, H-E, H-A-B-D-L2,
(X), (XI), (XIII) and (XIV) are known or may be prepared from known compounds by
methods familiar to those skilled in the art.
Depending on the identity of the group X, group Y, group R2, L, L2, L3 and L4 it may be
preferable for one or more of those groups to be protected during one or more steps of
the synthesis of a compound of formula (I). Suitable protecting groups are known to those
skilled in the art. Protecting groups may be any conventional protecting groups, for
example as described in "Protective Groups in Organic Synthesis" by Theodora Greene
and Peter G.M. Wuts (John Wiley and Sons Inc. 1999).
Enantiomeric compounds of the invention may be obtained (a) by the separation of the
components of the corresponding racemic mixture, for example, by chiral
chromatography, enzymatic resolution methods or preparing and separating suitable
diastereoisomers, (b) by direct synthesis from the appropriate chiral starting materials by
the methods described above, or (c) by methods analogous to those described above
using chiral reagents.
Optional conversion of a compound of formula (I) to a corresponding salt may
conveniently be effected by reaction with the appropriate acid or base. Optional
conversion of a compound of formula (I) to a corresponding solvate or other
physiologically functional derivative may be effected by methods known to those skilled in
the art.

Compounds of formula (I) may be useful for the treatment of any conditions in which
inhibition of matrix metalloproteinase would be beneficial, especially in the treatment of
inflammatory diseases and autoimmune disorders.
Examples of inflammatory conditions and autoimmune disorders in which the compounds
of the invention have potentially beneficial effects include diseases of the respiratory tract
such as asthma (including allergen-induced asthmatic reactions), cystic fibrosis, bronchitis
(including chronic bronchitis), chronic obstructive pulmonary disease (COPD), adult
respiratory distress syndrome (ARDS), chronic pulmonary inflammation, rhinitis and upper
respiratory tract inflammatory disorders (URID), ventilator induced lung injury, silicosis,
pulmonary sarcoidosis, idiopathic pulmonary fibrosis, bronchopulmonary dysplasia,
arthritis, e.g. rheumatoid arthritis, osteoarthritis, infectious arthritis, psoriatic arthritis,
traumatic arthritis, rubella arthritis, Reiter's syndrome, gouty arthritis and prosthetic joint
failure, gout, acute synovitis, spondylitis and non-articular inflammatory conditions, e.g.
herniated/ruptured/prolapsed intervertebral disk syndrome, bursitis, tendonitis,
tenosynovitic, fibromyalgic syndrome and other inflammatory conditions associated with
ligamentous sprain and regional musculoskeletal strain, inflammatory disorders of the
gastrointestinal tract, e.g. ulcerative colitis, diverticulitis, Crohn's disease, inflammatory
bowel diseases, irritable bowel syndrome and gastritis, multiple sclerosis, systemic lupus
erythematosus, scleroderma, autoimmune exocrinopathy, autoimmune encephalomyelitis,
diabetes, tumor angiogenesis and metastasis, cancer including carcinoma of the breast,
colon, rectum, lung, kidney, ovary, stomach, uterus, pancreas, liver, oral, laryngeal and
prostate, melanoma, acute and chronic leukemia, periodontal disease, neurodegenerative
disease, Alzheimer's disease, Parkinson's disease, epilepsy, muscle degeneration,
inguinal hernia, retinal degeneration, diabetic retinopathy, macular degeneration, ocular
inflammation, bone resorption diseases, osteoporosis, osteopetrosis, graft vs. host
reaction, allograft rejections, sepsis, endotoxemia, toxic shock syndrome, tuberculosis,
usual interstitial and cryptogenic organizing pneumonia, bacterial meningitis, systemic
cachexia, cachexia secondary to infection or malignancy, cachexia secondary to acquired
immune deficiency syndrome (AIDS), malaria, leprosy, leishmaniasis, Lyme disease,
glomerulonephritis, glomerulosclerosis, renal fibrosis, liver fibrosis, pancreatitis, hepatitis,
endometriosis, pain, e.g. that associated with inflammation and/or trauma, inflammatory
diseases of the skin, e.g. dermatitis, dermatosis, skin ulcers, psoriasis, eczema, systemic
vasculitis, vascular dementia, thrombosis, atherosclerosis, restenosis, reperfusion injury,
plaque calcification, myocarditis, aneurysm, stroke, pulmonary hypertension, left
ventricular remodeling and heart failure.
Diseases of principal interest include COPD and inflammatory diseases of the respiratory
tract and joints and vascular diseases.
It will be appreciated by those skilled in the art that reference herein to treatment extends
to prophylaxis as well as the treatment of established conditions.

There is thus provided as a further aspect of the invention a compound of formula (I) or a
physiologically acceptable derivative thereof for use in medicine.
According to another aspect of the invention, there is provided the use of a compound of
formula (I) or a physiologically acceptable derivative thereof for the manufacture of a
medicament for the treatment of inflammatory conditions or autoimmune disorders.
In a further or alternative aspect there is provided a method for the treatment of a human
or animal subject suffering from or susceptible to an autoimmune disorder or an
inflammatory condition which method comprises administering to said human or animal
subject an effective amount of a compound of formula (I) or a physiologically functional
derivative thereof.
The compounds according to the invention may be formulated for administration in any
convenient way, and the invention therefore also includes within its scope pharmaceutical
compositions comprising a compound of formula (I) or a physiologically acceptable
derivative thereof together, if desirable, with one or more physiologically acceptable
diluents or carriers.
There is also provided a process for preparing such a pharmaceutical formulation which
comprises mixing the ingredients.
The compounds according to the invention may, for example, be formulated for oral,
inhaled, intranasal, topical, buccal, parenteral or rectal administration, preferably for oral
administration.
Tablets and capsules for oral administration may contain conventional excipients such as
binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, mucilage of
starch, cellulose or polyvinyl pyrrolidone; fillers, for example, lactose, microcrystalline
cellulose, sugar, maize- starch, calcium phosphate or sorbitol; lubricants, for example,
magnesium stearate, stearic acid, talc, polyethylene glycol or silica; disintegrants, for
example, potato starch, croscarmellose sodium or sodium starch glycollate; or wetting
agents such as sodium lauryl sulphate. The tablets may be coated according to methods
well known in the art. Oral liquid preparations may be in the form of, for example, aqueous
or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry
product for constitution with water or other suitable vehicle before use. Such liquid
preparations may contain conventional additives such as suspending agents, for example,
sorbitol syrup, methyl cellulose, glucose/sugar syrup, gelatin, hydroxymethyl cellulose,
carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats; emulsifying
agents, for example, lecithin, sorbitan mono-oleate or acacia; non-aqueous vehicles
(which may include edible oils), for example almond oil, fractionated coconut oil, oily
esters, propylene glycol or ethyl alcohol; or preservatives, for example, methyl or propyl p-

hydroxybenzoates or sorbic acid. The preparations may also contain buffer salts,
flavouring, colouring and/or sweetening agents (e.g. mannitol) as appropriate.
Compounds according to the invention for topical administration may be formulated as
creams, gels, ointments or lotions or as a transdermal patch. Such compositions may for
example be formulated with an aqueous or oily base with the addition of suitable
thickening, gelling, emulsifying, stabilising, dispersing, suspending, and/or colouring
agents.
Lotions may be formulated with an aqueous or oily base and will in general also contain
one or more emulsifying agents, stabilising agents, dispersing agents, suspending agents,
thickening agents, or colouring agents. They may also contain a preservative.
For buccal administration the compositions may take the form of tablets or lozenges
formulated in conventional manner.
The compounds may also be formulated as suppositories, e.g. containing conventional
suppository bases such as cocoa butter or other glycerides.
The compounds according to the invention may also be formulated for parenteral
administration by bolus injection or continuous infusion and may be presented in unit dose
form, for instance as ampoules, vials, small volume infusions or pre-filled syringes, or in
multi-dose containers with an added preservative. The compositions may take such forms
as solutions, suspensions, or emulsions in aqueous or non-aqueous vehicles, and may
contain formulatory agents such as anti-oxidants, buffers, antimicrobial agents and/or
tonicity adjusting agents. Alternatively, the active ingredient may be in powder form for
constitution with a suitable vehicle, e.g. sterile, pyrogen-free water, before use. The dry
solid presentation may be prepared by filling a sterile powder aseptically into individual
sterile containers or by filling a sterile solution aseptically into each container and freeze-
drying.
The pharmaceutical compositions according to the invention may also be used in
combination with other therapeutic agents, for example anti-inflammatory agents (such as
corticosteroids (e.g. fluticasone propionate, beclomethasone dipropionate, mometasone
furoate, triamcinolone acetonide or budesonide) or NSAIDs (e.g. sodium cromoglycate,
nedocromil sodium, PDE-4 inhibitors, leukotriene antagonists, CCR-3 antagonists, iNOS
inhibitors, tryptase and elastase inhibitors, beta-2 integrin antagonists and adenosine 2a
agonists)) or beta adrenergic agents (such as salmeterol, salbutamol, formoterol,
fenoterol or terbutaline and salts thereof) or antiinfective agents (e.g. antibiotics,
antivirals).
It will be appreciated that when the compounds of the present invention are administered
in combination with other therapeutic agents normally administered by the inhaled or

intranasal route, that the resultant pharmaceutical composition may be administered by
the inhaled or intranasal route.
Compounds of the invention may conveniently be administered in amounts of, for
example, 0.01 to 100mg/kg body weight, preferably 0.1 to 25 mg/kg body weight, more
preferably 0.3 to 5mg/kg body weight,. The compounds may be given more than once
daily to be equivalent to the total daily dose. The precise dose will of course depend on
the age and condition of the patient and the particular route of administration chosen and
will ultimately be at the discretion of the attendant physician.
No toxicological effects are expected when a compound according to the present
invention is administered in the above mentioned dose range.
Compounds of the invention may be tested for in vitro activity in accordance with the
following assay:
The fluorescent peptide substrate used in the MMP-12 assay is FAM-Gly-Pro-Leu-Gly-
Leu-Phe-Ala-Arg-Lys(TAMRA), where FAM represents carboxyfluorescein, and TAMRA
represents tetramethylrhodamine. MMP12 catalytic domain (residues 106-268) protein
was expressed in E. coli in the form of insoluble inclusion bodies & stored in concentrated
solution under denaturing conditions (8M guanidine hydrochloride). Enzyme was
refolded into active form in situ by direct dilution into assay reactions. The 51 µL reactions
are run in NUNC-brand black.square 384-well plates, each well containing 2 µM
substrate, 20 nM enzyme, and 0.001-100 µM inhibitor, in 50 mM HEPES, pH 7.5,150 mM
NaCI, 10 mM CaCI2,1 µM ZnAc, 0.6 mM CHAPS, and 2 % DMSO. Postitive control wells
contain no inhibitor. Negative control wells are effected by either pre-dispensing the
EDTA quench (see below) or by omiting enyme. Reactions are incubated at ambient
temperature for 120 min, then quenched by the addition of 15µL of 100mM EDTA.
Product formation in each well is quantified by measuring flourescense with a Molecular
Devices Acquest. The excitation wavelength is set at 485 nM, and the emmision
wavelenght is 530 nM. IC50 values were obtained by first calculating the percent inhibition
(%l) at each inhibitor concentration (%l = 100*(1-(I-C2)/(C1-C2)), where C1 is the mean of
the positive controls, and C2 is the mean of the negative controls), then fitting the %l vs.
inhibitor concentration [I] data to: %I=A+((B-A)/(1+((C/[I]ˆD))), where A is the lower
asymptote, B is the upper asymptote, C is the IC50 value, and D is the slope factor. When
tested in this assay, compounds of Examples 1 to 12 had IC50s below 100 micromolar.
The invention may be illustrated by reference to the following examples, which should not
be construed as a limitation thereto:
General Experimental Details
LC/MS data were obtained under the following conditions:

• Column: 3.3cm x 4.6mm ID, 3um ABZ+PLUS
• Flow Rate: 3ml/min
• Injection Volume: 5µl
• Temp: RT
• UV Detection Range: 215 to 330nm
Solvents: A: 0.1% Formic Acid + 10mMolar Ammonium Acetate.
B: 95% Acetonitrile + 0.05% Formic Acid
Gradient: Time A% B%
0.00 100 0
0.70 100 0
4.20 0 100
5.30 0 100
5.50 100 0
1HNMR spectra were obtained at 400 MHz on a Bruker-Spectrospin Ultrashield 400
spectrophotometer.
Example 1: 5-Biphenyl-4-yl-2-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethyl]-3-
hydroxypentanoic acid

Potassium phthalimide (8.8 mg, 60 µmol) was added in one portion to a stirred solution of
1,1 -dimethylethy! 5-(4-biphenylyl)-3-({[4-(methyloxy)phenyl]methyl}oxy)-2-{2-
[(methylsulfonyl) oxy]ethyl}pentanoate (28.4 mg, 50 µmol) in dimethylformamide (0.5 mL)
under nitrogen at room temperature. The resulting solution was heated at 80 °C for 1 h
45 min then cooled to room temperature. The volatiles were evaporated and the residue
taken up in dichloromethane (0.5 mL). Trifloroacetic acid (0.5 mL) was added in one
portion and the resulting solution stirred for 1 h at room temperature. The volatiles were
evaporated and the residue purified by mass directed auto-preparative HPLC to give the
title compound as a white solid (6.0 mg, 27%). LC/MS: 3.43 min; z/e 444, calcd (M+1)
444. 1H NMR (400 MHz: CDCI3): 7.85 (2H), 7.70 (2H), 7.55 (1H), 7.50 (1H), 7.45 (2H),

7.30 (1H), 7.25 (4H), 3.85(3H), 2.95 (1H), 2.75 (1H), 2.60(1H), 2.20 (1H), 2.05 (1H), 1.90
(2H).
Example 2: 5-Biphenyl-4-yl-3-hydroxy-2-[2-(3-methyl-2,6-dioxo-3,6-dihydropyrimidin-
1(2H)-yl)ethyl]pentanoic acid

Prepared by an analogous reaction sequence to example 1. LC/MS: 2.96 min; z/e 423,
calcd(M+1)423.
Example 3: 5-Biphenyl-4-yl-3-hydroxy-2-[2-(3-methyl-2,4-dioxo-3,4-dihydropyrimidin-
1 (2H)-yl)ethyl]pentanoic acid

Prepared by an analogous reaction sequence to example 1. LC/MS: 2.98 min; z/e 423,
calcd(M+1) 423.
Example 4: 5-(4-Acetylbiphenyl-4-yl)-3-hydroxy-2-[2-(3-methyl-2,4-dioxo-3,4-
dihydropyrimidin-1(2H)-yl)ethyl]pentanoic acid

A solution of 3-hydroxy-5-(4-iodophenyl)-2-[2-(3-methyl-2,4-dioxo-3,4-dihydro-1 (2H)-
pyrimidinyl)ethyl]pentanoic acid (10 mg, 21 µmol) in dimethylformamide (0.5 mL) was

added in one portion to a mixture of p-acetylbenzeneboronic acid (4.0 mg, 25 nmol) and
fibrecat FC1001 (2.71% Pd; 8.3 mg, 2.0 µmol) in a Smith microwave reaction vial.
Aqueous sodium carbonate solution (1.0 M; 53 µL, 53 (imol) was added and the vial
capped. The crude reaction mixture was heated at 150 °C for 15 min using a Smith
Synthesiser microwave reactor. On cooling the vial was opened and the contents filtered
through a Whatman 5 µM filter tube, washing the filter cake with methanol (2x1 mL). The
filtrate was evaporated and the resulting residue was purified using mass directed auto-
preparative reverse phase HPLC to give the title compound (6.0 mg, 61 %) as a white
solid. LC/MS: 2.82 min; z/e 465, calcd (M+1) 465. H NMR (400 MHz: DMSO-d6): 8.00
(2H), 7.80 (2H), 7.60 (4H), 7.30 (2H), 6.65 (1H). 3.70 (3H), 3.10 (3H), 2.80 (1H), 2.60
(2H), 2.30 (1H), 1.85 (2H), 1.60 (1H).
Example 5: 3-Hydroxy-2-[2-(3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1 (2/-/)-yl)ethyl]-5-(4-
pyrimidin-5-ylphenyl)pentanoicacid

Prepared by an analogous reaction sequence to example 4. LC/MS: 2.27 min; z/e 425,
calcd (M+1) 425.
Example 6: 3-Hydroxy-2-[2-(3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1 (2H)-yl)ethyl]-5-[4-
(trifluoromethoxy)biphenyl-4-yl]pentanoic acid

Prepared by an analogous reaction sequence to example 4. LC/MS: 3.28 min; z/e 506,
calcd (M+1) 506.
Example 7: 5-[4-(1-Benzofuran-2-yl)phenyl]-2-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-
yl)ethyl]-3-hydroxypentanoic acid


A solution of 2-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethyl]-3-hydroxy-5-(4-
iodophenyl) pentanoic acid (25 mg, 50 nmol) in dimethylformamide (1.0 mL) was added in
one portion to a mixture of -benzofuran-2-ylboronic acid (11 mg, 70 µmol) and fibrecat
FC1001 (2.71% Pd; 20 mg, 5.0 µmol) in a Smith microwave reaction vial. Cesium
carbonate (41.0 mg, 125 µmol) was added and the vial capped. The crude reaction
mixture was heated at 150 °C for 15 min using a Smith Synthesiser microwave reactor.
On cooling the vial was opened and the contents partitioned between
methanol/dichloromethane (10:90; 10 mL) and aqueous hydrochloric acid solution (2.0 M;
10 mL). The organic phase was separated and filtered through a Whatman 5 µM filter
tube, washing the filter cake with methanol (2x1 mL). The filtrate was evaporated and the
resulting residue was purified using mass directed auto-preparative reverse phase HPLC
to give the title compound (3.0 mg, 12%) as a pale yellow solid. LC/MS: 3.69 min; z/e 484,
calcd (M+1) 484. 1H NMR (400 MHz: DMSO-d6): 7.80 (6H), 7.65 (2H), 7.30 (5H), 3.65
(1H), 3.60 (2H), 2.75 (1H), 2.55 (1H), 2.40 (1H major), 2.25 (1H minor), 1.85 (2H), 1.65
(2H).
Example 8: 2-[2-(1,3-Doxo-1,3-dihydro-2H-isoindol-2-yl)ethyl]-3-hydroxy-5-[4'-
(trifluoromethoxy)biphenyl-4-yl]pentanoic acid

Prepared by an analogous reaction sequence to example 7. LC/MS: 3.72 min; z/e 528,
calcd (M+1) 528.
Example 9: 2-[2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)ethyl]-3-hydroxy-5-[4'-
(methylthio)biphenyl-4-yl]pentanoic acid


Prepared by an analogous reaction sequence to example 7. LC/MS: 3.61 min; z/e 490,
calcd(M+1) 490.
Example 10: 5-(4'-Cyanobiphenyl-4-yl)-2-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethyl]-
3-hydroxypentanoic acid

Prepared by an analogous reaction sequence to example 7. LC/MS: 3.34 min; z/e 469,
calcd(M+1) 469.
Example 11: 5-(4'-Acetylbiphenyl-4-yl)-2-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethyl]-
3-hydroxypentanoic acid

Prepared by an analogous reaction sequence to example 7. LC/MS: 3.28 min; z/e 486,
calcd(M+1)486.
Example 12: 2-[2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)ethyl]-3-hydroxy-5-(4-pyrimidin-
5-ylphenyl)pentanoic acid


Prepared by an analogous reaction sequence to example 7. LC/MS: 2.70 min; z/e 446,
calcd(M+1)446.
Intermediate 1: 4-Bromomethyl-biphenyl

Carbon tetrabromide (8.99 g, 27.1 mmol) and triphenyl phosphine (7.11 g, 27.1 mmol)
were added to a stirred solution of biphenyl-4-yl methanol (5.00 g, 27.1 mmol) in
dichloromethane (100 mL) at room temperature. Stirring was continued at room
temperature for 1.5 hours then the solvent removed by evaporation under reduced
pressure. The residue was purified by column chromatography on silica gel (1:20 diethyl
ether: cyclohexane) to give the title compound (6.37g, 95%) as a white solid. 1H NMR
(400 MHz: CDCI3): 7.6 (4 H), 7.45 (4 H), 7.35 (1 H), 4.55 (2 H).
Intermediate 2: 5-Biphenyl-4-yl-3-oxo-pentanoic acid tert-butyl ester

A solution of f-butyl acetoaceate (1.84 mL, 11.1 mmol) in tetrahydrofuran (20 mL) was
added to a stirred suspension of sodium hydride (488 mg, 12.2 mmol) in tetrahydrofuran
(10 mL) at 0 °C under nitrogen. After stirring for 10 minutes n-butyl lithium (1.6 M in
hexanes; 7.3 mL, 11.6 mmol) was added dropwise over 2 minutes then stirring was
continued for a further 10 minutes. A solution of 4-bromomethyl-bipheny! (Intermediate 1,
3-00g, 12.2 mmol) in tetrahydrofuran (6 mL) was added dropwise over 10 minutes and the

resulting solution stirred at 0 °C for 1.5 hours. 6 M Hydrochloric acid (15 mL) was added;
then the crude reaction mixture was extracted with diethyl ether (3x50 mL). The organic
phases were combined, washed with brine (50 mL), dried (MgS04) then the solvent
evaporated under reduced pressure. The residue was purified by column chromatography
on silica gel (1:20 diethyl ether: cyclohexane) to give the title compound (1.37 g, 38%) as
a yellow solid. LC/MS: 3.78 min; z/e 342, calcd (M+NH4) 342.1H NMR (400 MHz: CDCI3):
7.55 (2 H), 7.50 (2 H), 7.43 (2 H), 7.32 (1 H), 7.25 (2 H). 3.34 (2 H), 2.95 (4 H), 1.45 (9 H).
Intermediate 3: terf-Butyl 5-biphenyl-4-yl-2-(2-{[ferf-butyl(dimethyl)silyl]oxy}ethyl)-3-
oxopentanoate

A solution of 5-biphenyl-4-yl-3-oxo-pentanoic acid tert-butyl ester (13.7 g, 42.4 mmol) in
dimethylformamide (10 mL) was added dropwise over 20 min to a stirred suspension of
sodium hydride (60% mineral oil suspension; 1.78 g, 44.4 mmol) in dimethylformamide
(10 mL) at 0 °C under nitrogen. After stirring for 20 min (2-bromoethoxy)-f-
butyldimethylsilane (10.0g, 46.4 mmol) was added dropwise over 20 min at 0 °C then the
reaction heated to 70 °C for 2.5 h. On cooling to room temperature the reaction was
quenched by careful addition of water (5 mL) then the volatiles evaporated. The residue
was partitioned between saturated aqueous ammonium chloride solution (200 mL) and
dichloromethane (200 mL) and the phases separated. The aqueous phase was washed
with dichloromethane (3x200 mL) then the organic phases combined, washed with brine
(200 mL), dried (sodium sulfate) and the solvent evaporated. The residue was
chromatographed on silica gel (10% diethyl ether: cyclohexane) to give the title compound
(12.1 g, 59%) as colourless oil which was a mixture of diastereomers. LC/MS: 4.70 min;
z/e 483, calcd (M+1) 483. 1H NMR (400 MHz: CDCI3): 7.55 (2H), 7.50 (2H), 7.40 (2H),
7.35 (1H), 7.25 (2H), 3.60 (2H), 2.95 (3H), 2.20 (1H minor) 2.0 (1H major), 1.55 (1H), 1.45
(11H), 0.85 (9H), 0.5 (6H).
Intermediate 4: tert-Butyl 5-biphenyl-4-yl-2-(2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)-3-
hydroxypentanoate


Sodium borohydride (1.05 g, 27.7 mmol) was added portion wise to a stirred solution of
tert-butyl 5-biphenyl-4-yl-2-(2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)-3-oxopentanoate (12.1 g,
25.2 mmol) in methanol (80 mL) at 0 °C under nitrogen. On completion of addition stirring
was continued for 1.5 h then the reaction was quenched with saturated aqueous
ammonium chloride solution (80 mL). The resulting mixture was extracted with diethyl
ether (3x200 mL) then the organic layers were combined, washed with brine (100 mL),
dried (magnesium sulfate) and the solvent evaporated. The residue was
chromatographed on silica gel (10% to 50% diethyl ether: cyclohexane) to give the title
compound (8.47 g, 69%) as a colourless oil which was a mixture of diastereomers.
LC/MS: 4.49 min; z/e 485, calcd (M+1) 485.1H NMR (400 MHz: CDCI3): 7.60 (2H), 7.50
(2H). 7.45 (2H), 3.90 (1H minor), 3.80 (1H minor), 3.70 (1H major), 3.65 (1H major), 3.25
(1H minor), 3.00 (1H major), 2.90 (1H), 2.75 (1H), 2.60 (1H major), 2.55 (1H minor), 1.90
(1H), 1.85 (2H), 1.45 (10 H), 0.90 (9H), 0.5 (6H).
Intermediate 5: 4-Methoxybenzyl 2,2,2-trichloroethanimidoate

4-Methoxybenzyl 2,2,2-trichloroethanimidoate was prepared using the procedure of
Smith, Amos B. lii; Qiu, Yuping; Kaufman, Michael; Arimoto, Hirokazu; Jones, David R.;
Kobayashi, Kaoru; Beauchamp, Thomas J. "Preparation of intermediates for the
synthesis of discodermolides and their polyhydroxy dienyl lactone derivatives for
pharmaceutical use" - WO 0004865.
Intermediate 6: 1,1-Dimethylethy! 5-(4-biphenylyl)-2-(2-{[(1.1-dimethylethyl)
(dimethyl)silyl]oxy}ethyl)-3-({[4-(methyloxy)phenyl]methyl}oxy)pentanoate


Boron trifluoride etherate (8.0 µL, 65 µmol) was added to a stirred solution of tert-butyl 5-
biphenyl-4-yl-2-(2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)-3-hydroxypentanoate (7.88 g, 16.3
mmol) and 4-methoxybenzyl 2,2,2-trichloroethanimidoate (6.88 g, 24.5 mmol) in
tetrahydrofuran (40 mL) at 0 °C under nitrogen. The reaction was allowed to warm to
room temperature at which stirring was continued for 2 h. A further portion of boron
trifluoride etherate (8.0 µL, 65 nmol) was then added and stirring was continued at room
temperature for a further 2 h. Two further additions of boron trifluoride etherate (8.0 µL,
65 µmol) followed by stirring at room temperature for 2 h were carried out before
evaporation of the solvent. The residue was chromatographed on silica gel (5% to 10%
diethyl ether: cyclohexane) to give the title compound (3.39 g, 34%) as a pale yellow oil
which was a mixture of diastereomers. LC/MS: 4.81 min; z/e 605, calcd (M+1) 605. 1H
NMR (400 MHz: CDCI3): 7.55 (2H), 7.45 (4H), 7.35-6.80 (7H), 4.50 (2H), 3.80 (3H), 3.60
(3H), 2.95 (1H), 2.80 (1H), 2.65 (1H), 1.85 (4H), 1.45 (9H), 0.85 (9H), 0.5 (6H).
Intermediate 7: 1,1-Dimethylethyl 5-(4-biphenylyl)-2-(2-hydroxyethyl)-3-({[4-
(methyloxy)phenyl]methyl}oxy)pentanoate

A solution of tetra-n-butylammonium fluoride (1.0 M in THF; 6.2 mL, 6.2 mmol) was added
dropwise over 15 min to a stirred solution of 1,1-dimethylethyl 5-(4-biphenylyl)-2-(2-{[(1,1-

dimethylethyl) (dimethyl)silyl]oxy}ethyl)-3-({[4-(methyloxy)phenyl]methyl}oxy)pentanoate
(3.39 g, 5.61 mmol) in tetrahydrofuran (20 mL) at 0 °C under nitrogen. The reaction was
allowed to warm to room temperature at which stirring was continued for 2 h. The
volatiles were evaporated and the residue partitioned between ethyl acetate (100 mL) and
water (100 mL). The phases were separated and the aqueous layer was washed with
ethyl acetate (3x100 mL). The organic layers were combined, washed with brine (100
mL), dried (magnesium sulfate) and the solvent evaporated. The residue was
chromatographed on silica gel (50% to 75% diethyl ether: cyclohexane) to give the title
compound (1.6 g, 58%) as a yellow oil which was a mixture of diastereomers. LC/MS:
3.98 min; z/e 491, calcd (M+1) 491.1H NMR (400 MHz: CDCI3): 7.55 (2H), 7.45 (4H), 7.30
(5H), 6.90 (2H), 4.50 (2H), 3.80 (3H), 3.65 (2H), 2.80 (2H), 2.65 (1H major), 2.05 (1H
minor), 1.85 (3H), 1.60-1.35 (11H).
Intermediate 8: 1,1-Dimethylethyl 5-(4-biphenylyl)-3-({[4-(methyloxy)phenyl]methyl}oxy)-
2-{2-[(methylsulfonyl)oxy]ethyl}pentanoate

Methanesulfonyl chloride (64 µL, 0.83 mmol) was added in one portion to a stirred
solution of 1,1-dimethylethyl 5-(4-biphenylyl)-2-(2-hydroxyethyl)-3-{{[4-
(methyloxy)phenyl]methyl}oxy) pentanoate (368 mg, 0.751 mmol) and triethylamine (15.4
mg, 209 µL, 1.52 mmol) in dichloromethane (2 mL) at room temperature under nitrogen.
After stirring at room temperature for 1 h the crude mixture was partitioned between
saturated aqueous citric acid solution (20 mL) and dichloromethane (20 mL). The phases
were separated and the organic layer was evaporated to give the title compound (409 mg,
79%) as a yellow oil which was a mixture of diastereomers. LC/MS: 4.08 min; z/e 586,
calcd (M+1) 586. 1H NMR (400 MHz: CDCI3): 7.50 (6H), 7.25 (4H), 7.15 (1H), 6.90 (2H),
4.50 (2H), 4.25 (2H), 3.80 (3H), 3.75 (1H), 2.95 (3H), 2.90-2.50 (3H), 2.05 (2H), 1.95-1.65
(2H), 1.55-1.35 (9H).
Intermediate 9: 5-(4-lodo-phenyl)-3-oxo-pentanoic acid tert-butyl ester


f-butylacetoacetate (1.5 mL, 9.2 mmol) was added dropwise over 2 minutes to a stirred
suspension of sodium hydride (60% mineral oil suspension; 400 mg, 10.0 mmol) in
tetrahydrofuran at 0 °C under nitrogen. After stirring for 10 minutes n-butyl lithium in
hexane (1.6 M; 6.0 mL, 9.6 mmol) was added then stirring continued for a further ten
minutes. The resulting solution was treated dropwise with a solution of 4-iodobenzyl
bromide (2.97 g, 10.0 mmol) in tetrahydrofuran (4 mL) and then warmed to room
temperature. The reaction was stirred for 40 minutes at room temperature and then
quenched with 6 M HCI (5 mL). The resulting mixture was extracted with diethyl ether
(3x50 mL). The organic phases were combined, washed with brine (50 mL) and dried
(MgSO4) then the solvent evaporated under reduced pressure. The residue was purified
via flash chromatography on silica gel (1:20 to 1:10 ethyl acetate / cyclohexane) to give
the title compound (1.88 g, 54%) as a yellow oil. LC/MS: 3.66 min; z/e 375, calcd (M+1)
375. 1H NMR (400 MHz; CDCI3): 7.6 (2 H), 6.93 (2 H), 3.33 (2 H), 2.85 (4 H), 1.45 (9 H).
Intermediate 10: 1,1-Dimethylethyl 2-(2-{[(1,1-dimethylethyl)(dimethyl)silyl]oxy}ethyl)-5-
(4-iodophenyl)-3-oxopentanoate

A solution of 5-(4-iodo-phenyl)-3-oxo-pentanoicacid tert-butyl ester (10.0 g, 26.7 mmol) in
dimethylformamide (25 mL) was added dropwise over 20 min to a stirred suspension of
sodium hydride (60% mineral oil suspension; 1.12 g, 28.0 mmol) in dimethylformamide
(25 mL) at 0 °C under nitrogen. After stirring for 20 min (2-bromoethoxy)-f-
butyldimethylsilane (7.03g, 6.31 mL, 29.4 mmol) was added dropwise over 20 min at 0 °C
then the reaction heated to 70 °C for 3.5 h. On cooling to room temperature the reaction
was quenched by careful addition of water (2 mL) then the volatiles evaporated. The
residue was partitioned between saturated aqueous ammonium chloride solution (150
mL) and dichloromethane (150 mL) and the phases separated. The aqueous phase was
washed with dichloromethane (3x150 mL) then the organic phases combined, washed
with brine (150 mL), dried (sodium sulfate) and the solvent evaporated. The residue was
chromatographed on silica gel (25% diethyl ether: cyclohexane) to give the title compound
(10.0 g, 70%) as colourless oil which was a mixture of diastereomers. LC/MS: 4.55 min;

2/e 533, calcd (M+1) 533. 1H NMR (400 MHz: CDCI3): 7.55 (2H), 6.90 (2H), 3.55 (3H),
2.85 (4H), 2.15 (2H minor), 1.95 (2H major), 1.40 (9H), 0.85 (9H), 0.5 (6H).
Intermediate 11: 1,1-Dimethylethyl 2-(2-{[(1,1-dimethylethyl)(dimethyl)silyl]oxy}ethyl)-3-
hydroxy-5-(4-iodophenyl)pentanoate

Sodium borohydride (0.59 g, 15.6 mmol) was added portion wise to a stirred solution of
1,1-dimethylethyl 2-(2-{[(1,1-dimethylethyl)(dimethyl)silyl]oxy}ethyl)-5-(4-iodophenyl)-3-
oxopentanoate (7.55 g, 14.2 mmol) in methanol (100 mL) at 0 °C under nitrogen. On
completion of addition stirring was continued for 1.5 h then the reaction was quenched
with saturated aqueous ammonium chloride solution (100 mL). The resulting mixture was
extracted with diethyl ether (3x200 mL) then the organic layers were combined, washed
with brine (100 mL), dried (sodium sulfate) and the solvent evaporated. The residue was
chromatographed on silica gel (25% to 50% diethyl ether: cyclohexane) to give the title
compound (5.14 g, 68%) as a colourless oil which was a mixture of diastereomers.
LC/MS: 4.72 min; z/e 535, calcd (M+1) 535.1H NMR (400 MHz: CDCI3): 7.55 (2H), 6.95
(2H), 3.85-3.55 (3H), 3.30 (1H minor), 3.00 (1H major), 2.80 (1H), 2.65 (1H), 2.55 (1H
major), 2.50 (1H minor), 1.95-1.65 (4H), 1.45 (9H), 0.90 (9H), 0.5 (6H).
Intermediate 12: 1,1-Dimethylethyl 2-(2-{[(1,1-dimethylethyl)(dimethyl)silyl]oxy}ethyl)-5-
(4-iodophenyl)-3-({[4-(methyloxy)phenyl]methyl}oxy)pentanoate

Boron trifluoride etherate (5.0 µL, 39 µmol) was added to a stirred solution of 1,1-
dimethylethyl 2-(2-{{(1,1 -dimethylethyi)(dimethyl)siiyl]oxy}ethyl)-3-hydroxy-5-(4-

iodophenyl)pentanoate (5.14 g, 9.63 mmol) and 4-methoxybenzyl 2,2,2-
trichloroethanimidoate (4.05 g, 14.4 mmol) in tetrahydrofuran (40 mL) at 0 °C under
nitrogen. The reaction was allowed to warm to room temperature at which stirring was
continued for 2 h. A further portion of boron trifluoride etherate (5.0 µL, 39 µmol) was then
added and stirring was continued at room temperature for a further 2 h. Two further
additions of boron trifluoride etherate (5.0 µL, 39 µmol) followed by stirring at room
temperature for 2 h were carried out before evaporation of the solvent. The residue was
chromatographed on silica gel (0% to 10% diethyl ether: cyclohexane) to give the title
compound (4.14 g, 66%) as a yellow oil which was a mixture of diastereomers. LC/MS:
4.78 min; z/e 655, calcd (M+1) 655.1H NMR (400 MHz: CDCI3): 7.55 (2H), 7.25 (2H), 6.90
(2H), 6.80 (2H), 4.55 (1H), 4.35 (1H), 3.80 (3H), 3.65 (1H), 3.55 (1H), 2.95 (1H major),
2.80 (1H minor). 2.70 (1H), 2.55 (1H), 1.95-1.60 (4H), 1.45 (9H), 0.85 (9H), 0.5 (6H).
Intermediate 13: 1,1-Dimethylethyl 2-(2-hydroxyethyl)-5-(4-iodophenyl)-3-({[4-
(methyloxy)phenyl]methyl}oxy)pentanoate

A solution of tetra-n-butylammonium fluoride (1.0 M in THF; 7.0 mL, 7.0 mmol) was added
dropwise over 15 min to a stirred solution of 1,1-dimethylethyl 2-(2-{[(1,1-
dimethylethyl)(dimethyl)silyl]oxy}ethyl)-5-(4-iodophenyl)-3-({[4-
(methyloxy)phenyl]methyl}oxy) pentanoate (4.14 g, 6.33 mmol) in tetrahydrofuran (25 mL)
at 0 °C under nitrogen. The reaction was allowed to warm to room temperature at which
stirring was continued for 2 h. The volatiles were evaporated and the residue partitioned
between ethyl acetate (100 mL) and water (100 mL). The phases were separated and the
aqueous layer was washed with ethyl acetate (3x100 mL). The organic layers were
combined, washed with brine (100 mL), dried (magnesium sulfate) and the solvent
evaporated. The residue was chromatographed on silica gel (25% to 50% ethyl acteate:
cyclohexane) to give the title compound (2.87 g, 84%) as a yellow oil which was a mixture
of diastereomers. LC/MS: 3.86 min; z/e 541, calcd (M+1) 541.1H NMR (400 MHz: CDCI3):
7.55-7.25 (4H), 6.90-6.75 (4H), 4.55-4.35 (2H), 3.80 (3H), 3.65 (3H), 2.90-2.45 (3H), 1.90-
1.60 (4H), 1.35 (9H).

Intermediate 14 1,1-Dimethylethyl 5-(4-iodophenyl)-3-({[4-(methyloxy)phenyl]methyl}oxy)-
2-{2-[(methylsulfonyl)oxy]ethyl}pentanoate

Methanesulfonyl chloride (315 µL, 5.91 mmol) was added in one portion to a stirred
solution of 1,1-dimethylethyl 2-(2-hydroxyethyl)-5-(4-iodophenyl)-3-({[4-
(methyloxy)phenyl]methyl}oxy) pentanoate (2.00 g, 3.70 mmol) and triethylamine (1.03
mL, 7.39 mmol) in dichloromethane (10 mL) at room temperature under nitrogen. After
stirring at room temperature for 1 h the crude mixture was partitioned between saturated
aqueous citric acid solution (40 mL) and dichloromethane (40 mL). The phases were
separated and the organic layer was evaporated to give the title compound (2.3 g, 100%)
as a yellow oil which was a mixture of diastereomers. LC/MS: 4.00 min; z/e 636, calcd
(M+18) 636. 1H NMR (400 MHz: CDCI3): 7.60-7.20 (4H), 6.90-6.75 (4H), 4.60-4.20 (5H),
3.80 (3H), 2.95 (3H), 2.90-2.45 (3H), 2.10-1.70 (4H), 1.40 (9H).
Intermediate 15: 1,1-Dimethylethyl 2-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethyl]-5-
(4-iodophenyl)-3-({[4-(methyloxy)phenyl]methyl}oxy)pen1anoate


Potassium phthalimide (0.33 g, 2.2 mmol) was added in one portion to a stirred solution of
1,1 -dimethylethyl 5-(4-iodophenyl)-3-({[4-(methyloxy)phenyl]methyl}oxy)-2-{2-
[(methylsulfonyl)oxy]ethyl}pentanoate (1.15 g, 1.86 mmol) in dimethylformamide (6 mL) at
room temperature under nitrogen. The resulting solution was heated at 80 °C for 1 h 45
min then cooled to room temperature. The volatiles were evaporated and the residue
partitioned between dichloromethane (50 mL) and water (50 mL). The layers were
separated and the organic phase evaporated to dryness. The residue was
chromatographed on silica gel (50% ethyl acetate: cyclohexane) to give the title
compound (0.26 g, 21%) as a yellow oil which was a mixture of diastereoisomers. LC/MS:
4.29 min; z/e 687. calcd (M+18) 687.1H NMR (400 MHz: CDCI3): 7.85 (2H), 7.70 (2H),
7.55-7.20(4H), 6.90-6.75 (4H), 4.55-4.30 (2H), 3.80 (3H), 3.75 (1H), 3.65 (2H), 2.80-2.45
(3H). 2.10-1.50 (4H), 1.40 (9H).
Intermediate 16 1,1-Dimethylethyl 5-(4-iodophenyl)-2-[2-(3-methyl-2,4-dioxo-3,4-dihydro-
1(2H)-pyrimidinyl)ethyl]-3-({[4-(methyloxy)phenyl]methyl}oxy)pentanoate

3-Methyl-2,4(1H,3H)-pyrimidinedione (0.28 g, 2.2 mmol) was added in one portion to a
stirred suspension of sodium hydride (60% suspension in mineral oil; 80 mg, 2.0 mmol) in
dimethylformamide (3 mL) at room temperature under nitrogen. The resulting suspension
was stirred for 5 min then a solution of 1,1-dimethylethyl 5-(4-iodophenyl)-3-({[4-
(methyloxy)phenyl]methyl}oxy)-2-{2-[(methylsulfonyl)oxy]ethyl}pentanoate (1.15 g, 1.86
mmol) in dimethylformamide (3 mL) was added in one portion. The resulting solution was
heated at 80 °C for 1 h 45 min then cooled to room temperature. The volatiles were
evaporated and the residue partitioned between dichloromethane (50 mL) and water (50
mL). The layers were separated and the organic phase evaporated to dryness. The
residue was chromatographed on silica gel (10% methanol: dichloromethane) to give the
title compound (0.33 g, 27%) as a yellow oil which was a mixture of diastereomers.
LC/MS: 3.87 min; z/e 649, calcd (M+1) 649. 1H NMR (400 MHz: CDCI3): 7.55 (2H), 7.25

(2H), 7.10 (1H), 6.90-6.75 (4H), 5.70 (1H), 4.40 (2H), 3.85-3.60 (6H), 3.75-2.45 (3H),
2.00-1.70(4H), 1.40 (9H).
Intermediate 17 2-[2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)ethyl]-3-hydroxy-5-(4-
iodophenyl)pentanoic acid

Trifluoroacetic acid (5 ml_) was added in one portion to a stirred solution of 1,1-
dimethylethyl 2-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethyl]-5-(4-iodophenyl)-3-({[4-
(methyloxy)phenyl]methyl}oxy)pentanoate (261 mg, 0.390 mmol) in dichloromethane (5
mL) at room temperature under nitrogen. The resulting solution was stirred for 45 min
then the volatiles evaporated to give the title compound (192 mg, 100%) as a yellow solid
which was a mixture of diastereomers. LC/MS: 3.32 min; z/e 493, calcd (M+1) 493. 1H
NMR (400 MHz: CDCI3): 7.85 (4H), 7.55 (2H), 6.95 (2H), 4.90 (1H), 3.80-3.50 (3H), 2.70-
2.20 (3H), 1.85 (2H), 1.55 (2H).
Intermediate 18: 3-Hydroxy-5-(4-iodophenyl)-2-[2-(3-methyl-2,4-dioxo-3,4-dihydro-1 (2H)-
pyrimidinyl)ethyl]pentanoic acid

Prepared by an analogous reaction to intermediate 17. LC/MS: 2.85 min; z/e 473, calcd
(M+1) 473.

WE CLAIM:
1. A compound as claimed in claim 1 of formula (la):

wherein:
G1 and G2 each independently represents CH or N;
A is absent, or when present, it represents C1-6alkylene or CH=CH-C1-4alkylene ;
B is absent, or when present, it represents O, S, SO, SO2, CO, CR7R8, C02R14,
CONR14R15, N(COR14)(COR15), N(SO2R14)(COR15), NR14R15;
D is absent, or when present, it represents C1-6 alkylene ;
E represents aryl substituted by one or more of C1-6 alkyl, C2-6 alkenyl, halogen, C1-6
alkoxy, cyano, hyoroxy, nitro, amino, -N(CH3)2, -MHCOC1-6 alkyl, -OCF3, -CF3, -COOC1-6
alkyl, -OCHCF2, -SCF3, -CONR5R6, -SO2N(CH3)2, -SO2CH3 or -SCH3 groups, or by fused
cycloalkyl or heterocyclic rings which may themselves be substituted, for example by
carbonyl groups;or unsubstituted heteroaryl; or heteroaryl substituted by one or more of
C1-6 alkyl, C2-6 alkenyl, halogen, C1-6 alkoxy, cyano, hydroxy, nitro, amino, -N(CH3)2, -
MHCOC1-6 alkyl, -OCF3, -CF3, -COOC1-6 alkyl, -OCRCF2, -SCF3, -CONR5R6 -SO2N(CI-l3)2,
-SO2CH3 or -SCH3 groups, or by fused cycloalkyl or heterocyclic rings which may
themselves be substituted, for example by carbonyl groups; wherein heteroaryl means
mono- or bicyclic heterocyclic aromatic rings containing 1-3 hetero atoms selected from
nitrogen, oxygen and sulphur;
R5 and R5 each independently represent M, C1-6 alkyl or C1-4 alkylaryl;
R7 and R3 each independently represent H, halo, C1-6 alkyl or C1-4 alkylaryl;
R14 and R15 each independently represent H, C1-6alkyl, C1-4 alkylaryl or C1-4 alkylheteroaryl
or together with the functionality to which they are attached R14 arid R15 form a
heterocyclic or fused heterocyclic group which may contain one or more further atoms
selected from C, O, N and S;
R16represents H, C1-6 alkyl or C1-4 alkylaryl;
R17 represents H or C1-6 alkyl;
R15 and R13 each independently represents halo, cyano, nitro, OR15, SR16, COR15,
NR17COR13, CONR16R17 optionally substituted phenoxy or C1-6alkyl optionally substituted
by OR18;

m and n each independently represents 0 or an integer 1,2 or 3;
and pharmaceutically acceptable esters, amides and carbamates, salts and solvates
thereof.
2. A compound as claimed in claim 1 wherein n is 0 and m is I.
3. A compound as claimed in claim 1 wherein the compound is a compound of formula (Ic):

A is absent, or when present, it represents C1-6 alkylene or CH=CH-C1-4alkylene ;
B is absent, or when present, it represents O, S, SO, SO2, CO, CR7R8, CO2R14,
CONR14R15, N(COR14)(COR15), N(SO2R14)(COR15), NR14R15;
D is absent, or when present, it represents C1-6 alkylene ;
E represents aryl substituted by one or more of C1-6 alkyl, C2-6 alkenyl, halogen, C1-6
alkoxy, cyano, hydroxy, nitro, amino, -N(CH3)2, -NHCOC1-6 alkyl, -OCF3, -CF3, -COOC1-6
alkyl, -OCHCF2, -SCF3, -CONR5R6 -SO2N(CH3)2, -SO7CH3 or -SCH3 groups, or by fused
cycloalkyl or heterocyclic rings which may themselves be substituted, for example by.
carbonyl groups; or unsubstituted heteroaryl; or heteroaryl substituted by one or more of
C1-6 alkyl, C2-6 alkenyl, halogen, C1-6 alkoxy, cyano, hydroxy, nitro, amino, -N(CH3)2, -
NHCOC1-6, alkyl, -OCF3, -CF3, -COOC1-6 alkyl, -OCHCF2, -SCF3, -CONR5R6 -SO2N(CH3)2,
-SO2CH3 or -SCH3 groups, or by fused cycloalkyl-or heterocyclic rings which may
themselves be substituted, (or example by carbonyl groups; wherein heteroaryl means
mono- or bicyclic heterocyclic aromatic rings containing 1-3 hetero atoms selected from.
nitrogen, oxygen and sulphur;
R5 and R6 each independently represent H, C1-6 alkyl or C1-4 alkylaryl;
R7 and R6 each independently represent H, halo, C1-6 alkyl or C1-4 alkylaryl;
R14 and R15 each independently represent H, C1-6 alkyl, C1-4 alkylaryl or C1-4 alkylheteroaryl
or together with the functionality to which they are attached R14 and R15 form a
heterocyclic or fused heterocyclic group which may contain one or more further atoms
selected from C, O, N and S;
R16 represents H, C1-6 alkylo or C1-4 alkylaryl;
R17 represents H or C1-6 alkyl:

R18 and.R19 each independently represents halo, cyano, nitro, OR16, SR16, COR ,
NR17COR15, CONR16R7, optionally substituted phenoxy or C1-6alkyl optionally substituted
by OR16;
m and n each independently represents 0 or an integer 1,2 or 3;
and pharmaceutically acceptable esters, amides and carbamates, salts and solvates
thereof such as herein described.
4. A compound as claimed in any one of claims 1 to 3 wherein A-B-D represents
CH2CH2-.
5. A compound as claimed in any one of claims 1 to 4 wherein E represents aryl such as herein described
substituted by one or more of C1-6 alkyl, C2-6 alkenyl, halogen, C1-6alkoxy, cyano, hydroxy,
nitro, amino, -N(CH3)2, -NHCOC1-6 alkyl, -OCF3, -CF3, -COOC1-6 alkyl, -OCHCF2, -3CF3, -
CONR5R6 -SO2N(CH3)2, -SO2CH3 or -SCH3 groups, or by fused cycio.aikyi or heterocyciic
rings which may themiselves be substituted, for example by carbonyl groups.
6. A compound as claimed in any one of claims 1 to 4 wherein E represents
unsubstituted heteroaryl such as herein described.
7. A compound as claimed in any one of claims 1 to 4 wherein E represents heteroaryl
substituted by one or more of C1-6 alkyl, C2-6 alkenyl, halogen, C1-6 alkoxy, cyano, hydroxy,
nitro, amino, -N(CH3)2, -NHCOC1-6 alkyl, -OCF3, -CF3, -COOC1-6 alkyl, -OCHCF2, -SCF3, -
CONR5R6 -SO2N(CH3)2, -SO2CH3, or -SCH3 groups, or by fused cycloalkyl or heterocyclic
rings which may themselves be substituted, for example by carbonyl groups.
8. A compound selected from:
5-Bipheny!-4-yl-2-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethyl]-3-hydroxypentanoic
acid;
5-Biphenyl-4-yl-3-hydroxy-2-[2-(3-methyl-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-
yl)ethyl]pentanoic acid;
5-Biphenyl-4-yl-3-hydroxy-2-[2-(3-methy-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-
yl)ethyl]pentanoic acid;
5-(4'-Acetylbiphenyl-4-yl)-3-hydroxy-2-[2-(3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-
yl)ethyl]pentanoic acid;
3-Hydroxy-2-[2-(3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethyl]-5-(4-pyrimidin-5-
ylphenyl)pentanoic acid;
3-Hydroxy-2-[2-(3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethyl]-5-[4'-
(trifluoromethoxy)biphenyl-4-yl]pentancic acid;
5-[4-(1-Benzofuran-2-yl)phenyl]-2-[2-(1,3-dioxo-1,3-dihycro-2H-isoindol-2-yl)ethyl]-3-
hydroxypentanoic acid;
2-[2-(1,3-DoxG-13-dihydro-2H-isoindol-2-yl)ethyl]-3-hydroxy-5-[4'-
(trifluoromethonoxy)biphenyl-4-yl]pentanoic acid;

2-[2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)ethyl]-3-hydroxy-5-[4-(methylthio)biphenyl-4-
yl]pentanoic acid;
5-(4'-Cyanobiphenyl-4-yl)-2-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethyl]-3-
hydroxypentanoic acid;
5-(4'-Acetylbiphenyl-4-yl)-2-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethyl]-3-
hydroxypentanoic acid; and
2-[2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)ethyl]-3-hydroxy-5-(4-pyrimidin-5-
ylphenyl)pentanoic acid;
and pharmaceutically acceptable esters, amides and carbamates, salts and solvates
thereof.
9. A compound as claimed in any one of claims 1 to 8 for use in medicine.
10. A pharmaceutical composition comprising a compound as claimed in any one of
claims 1 to 8 and a pharmaceutically acceptable carrier therefor, and optionally one or
more other therapeutic agents.
11. A process for the preparation of compounds of formula (la) wherein T is absent as
defined in claim 1, which process comprises:
(A) reacting a compound of formula (II):

wherein R1, R1' and R3 each represents H; A. B, D, E are as defined for formula (la) in
claims 1 to 4; Q represents;

X represents CH2;Y represents CHOH; R2 represents COOH and L represents a leaving
group, with a reagent

(B) reacting a compound of formula (VII):

wherein Q, X, Y, R1, R1', R2, R3, R4, A, B and D are as previously defined for formula (II), Z
represents a bond, L represents a leaving group and R4 represents a group
(C) carrying out a process selected from processes (A) to (B) followed by oxidation,
reduction, substitution or deprotection.

Compounds of Formula (la) : Wherein T is absent, represents optional bonds, G1 and G2
each independently represents CH or N, A represents bond, C1-6alkyl or CH=CH-C1-4alkyl, B
represents bond, O, S, SO, SO2, CO, CR7R8, CO2R14, CONR14R15, N(COR14)(COR15),
N(SO2R14)(COR15), NR14R15, D represents bond, or C1-6 alkyl, E represents aryl substituted by
one or more of C1-6 alkyl, C2-6 alkenyl, halogen, C1-6 alkoxy, cyano, hydroxy, nitro, amino, -
N(CH3)2, -NHCOC1-6 alkyl, -OCF3, -CF3, -COOC1-6 alkyl, -OCHCF2, -SCF3, -CONR5R6 -
SO2N(CH3)2, -SO2CH3 or -SCH3 groups, or by fused cycloalkyl or heterocyclic rings which may
themselves be substituted, for example by carbonyl groups;or unsubstituted heteroaryl; or
heteroaryl substituted by one or more of C1-6 alkyl, C2-6 alkenyl, halogen, C1-6 alkoxy, cyano,
hydroxy, nitro, amino, -N(CH3)2, -NHCOC1-6 alkyl, -OCF3, -CF3, -COOC1-6 alkyl, -OCHCF2, -SCF3,
-CONR5R6 -SO2N(CH3)2, -SO2CH3 or -SCH3 groups, or by fused cycloalkyl or heterocyclic rings
which may themselves be substituted, for example by carbonyl groups; wherein heteroaryl
means mono- or bicyclic heterocyclic aromatic rings containing 1-3 hetero atoms selected from
nitrogen, oxygen and sulphur, R5 and R6 each independently represent H, C1-6 alkyl or C1-4
alkylaryl, R7 and R8 each independently represent H, halo, C1-6 alkyl or C1-4 alkylaryl, R14 and R15
each independently represents H, C1-6 alkyl or C1-4 alkylaryl or C1-4 alkylheteroaryl or together with
the functionality to which they are attached R14 and R15 from a heterocyclic or fused heterocyclic
group which may contain one or more further atoms selected from C, O, N and S, R16 represents
H, C1-6 alkyl or C1-4 alkylaryl, R17 represents H or C1-6 alkyl, R18 and R19 each independently
represents halo, cyano, nitro, OR16, SR16, COR16, NR17COR16, CONR16R17, optionally substituted
phenoxy or C1-6alkyl optionally substituted by OR16, m and n each independently represents 0 or
an integer 1,2 or 3and pharmaceutically acceptable esters, amides and carbamates, salts and
solvates thereof.

Documents:

295-KOLNP-2006-FORM-27-1.pdf

295-KOLNP-2006-FORM-27.pdf

295-kolnp-2006-granted-abstract.pdf

295-kolnp-2006-granted-assignment.pdf

295-kolnp-2006-granted-claims.pdf

295-kolnp-2006-granted-correspondence.pdf

295-kolnp-2006-granted-description (complete).pdf

295-kolnp-2006-granted-examination report.pdf

295-kolnp-2006-granted-form 1.pdf

295-kolnp-2006-granted-form 13.pdf

295-kolnp-2006-granted-form 18.pdf

295-kolnp-2006-granted-form 3.pdf

295-kolnp-2006-granted-form 5.pdf

295-kolnp-2006-granted-gpa.pdf

295-kolnp-2006-granted-reply to examination report.pdf

295-kolnp-2006-granted-specification.pdf


Patent Number 230348
Indian Patent Application Number 295/KOLNP/2006
PG Journal Number 09/2009
Publication Date 27-Feb-2009
Grant Date 25-Feb-2009
Date of Filing 10-Feb-2006
Name of Patentee GLAXO GROUP LIMITED
Applicant Address GLAXO WELLCOME HOUSE, BERKELEY, AVENUE, GREENFORD, MIDDLESEX, UB6 0NN
Inventors:
# Inventor's Name Inventor's Address
1 GAINES, SIMON GLAXOSMITHKLINE, GUNNELS WOOD ROAD, STEVENAGE HERTFORDSHIRE SG1 2NY
2 HOLMES, IAN, PETER GLAXOSMITHKLINE, GUNNELS WOOD ROAD, STEVENAGE HERTFORDSHIRE SG1 2NY
3 MARTIN, STEPHEN, LEWIS GLAXOSMITHKLINE, GUNNELS WOOD ROAD, STEVENAGE HERTFORDSHIRE SG1 2NY
4 WATSON, STEPHEN, PAUL GLAXOSMITHKLINE, GUNNELS WOOD ROAD, STEVENAGE HERTFORDSHIRE SG1 2NY
PCT International Classification Number C07D 209/48
PCT International Application Number PCT/EP2004/010319
PCT International Filing date 2004-09-10
PCT Conventions:
# PCT Application Number Date of Convention Priority Country
1 0321538.1 2003-09-13 U.K.